Maggie Segall Speaks at PLI’s Hot Topics for In‑House Counsel 2023 Program
October 02, 2023
On September 29, 2023, Cravath partner Margaret T. Segall participated in “Hot Topics for In‑House Counsel 2023,” a program presented by the Practising Law Institute in New York. Maggie spoke on a panel entitled “The Evolving Domestic and International Antitrust Landscape,” which reviewed developments in the domestic and international antitrust landscape, including new approaches to mergers, conduct cases, remedies and potential legislative changes.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 2008, Harvard Law Schoolcum laude
-
A.B., 2003, Harvard Collegemagna cum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
October 02, 2023
Cisco’s Proposed Acquisition of Splunk
On September 21, 2023, Cisco, a leading global technology company, and Splunk, a cybersecurity and observability leader, announced a definitive agreement under which Cisco intends to acquire Splunk for $157 per share in cash, representing approximately $28 billion in equity value. Cravath is representing Cisco on regulatory matters in connection with the transaction.
Deals & Cases
October 02, 2023
Viatris’s $6.94 Billion in Announced Divestitures
On October 1, 2023, Viatris Inc. (“Viatris”), a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (“OTC”) business, and has entered into definitive agreements to divest its Women’s Healthcare business, its Active Pharmaceutical Ingredient (“API”) business in India and commercialization rights in certain non-core markets that were acquired as part of the combination with Upjohn. The total transactions value, including Viatris’s 2022 divestiture of its biosimilars business, represents up to $6.94 billion of total gross proceeds. The estimated transaction value for the divestitures announced today is $3.6 billion, including gross consideration of up to approximately $2.17 billion for the divestiture of substantially all of its OTC business, and up to approximately $1.2 billion combined for the divestitures of its API and Women’s Healthcare businesses. Cravath is representing Viatris in connection with the transactions.
Deals & Cases
September 11, 2023
Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
August 07, 2023
Tabula Rasa’s Acquisition by Nautic
On August 7, 2023, Tabula Rasa HealthCare, Inc.® (“Tabula Rasa”), a leading healthcare company advancing personalized, comprehensive care for value‑based care organizations, announced it has entered into a definitive agreement to be acquired by Nautic Partners (“Nautic”) for $10.50 in cash per share and will combine with ExactCare Pharmacy, a portfolio company of Nautic. The all‑cash transaction values Tabula Rasa at approximately $570 million, including net debt of approximately $262 million, on an enterprise value basis. Cravath is representing Tabula Rasa in connection with the transaction.
